Tratamiento para la leucemia promielocítica aguda. Tratamiento para la . llamado anemia. La anemia puede causar cansancio o dificultad para respirar. vol número2 · Estudio longitudinal de anticuerpos anticitoplasma de neutrófilos en pacientes con anemia drepanocítica · Sistema analítico de evaluación de. Request PDF on ResearchGate | Leucemia promielocítica aguda. Comportamiento clínico | Background: Acute promyelocytic leukemia is a peculiar form of non-.

Author: Voodoolkree Moogushicage
Country: Kenya
Language: English (Spanish)
Genre: Business
Published (Last): 4 July 2004
Pages: 298
PDF File Size: 13.51 Mb
ePub File Size: 1.24 Mb
ISBN: 574-9-58539-578-8
Downloads: 47669
Price: Free* [*Free Regsitration Required]
Uploader: Dugul

From the molecular model to the impact on prognosis: Acute promyelocytic leukemia APL is a model of clinical applicability of the knowledge of molecular physiopathology. It is characterized by recurrent genetic involvement of the retinoic acid alpha receptor.

Acute promyelocytic leukemia – Wikipedia

The consequence is a protein with low sensibility to its ligand and a myeloid maturation arrest. Epidemiologically, it differs from other acute myeloid leukemia due to a higher incidence in young adults and in countries of “Latin” colonization.

Differing from excellent results observed in developed countries, APL mortality in Brazil is still high, despite the wide availability of drugs.

Assim como nas outras LMAs, sintomas constitucionais como febre, astenia, hiporexia e perda ponderal predominam. Medidas de controle da coagulopatia. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. The apparent excess of acute promyelocytic leukemia in infant acute leukemias in Brazil. Proposals for the classification of the acute leukaemias. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.

Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia.

A previously uncharacterized gene, PML, is fused to the retinoic acid receptor alpha gene in acute promyelocytic leukaemia. Melnick A, Licht JD. RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia.


Acute promyelocytic leukemia

International Union peomielocitica Pharmacology. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Continuous treatment with all-trans retinoic acid snemia a progressive reduction in plasma drug concentrations: Role of promyelocytic lromielocitica PML protein in tumor suppression. PML is essential for multiple apoptotic pathways. Variations on a theme: Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.

Inferior prognostic outcome in acute promyelocytic leukemia with alterations of FLT3 gene. The epidemiology of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia AML in Spain. About the increased frequency of acute promyelocytic leukemia among Latinos: Braz J Med Biol Res.

PML-RARalpha fusion gene transcripts and biological features in acute promyelocytic leukemia patients. More on geographic hematology: Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. Acute promyelocytic prromielocitica in 57 previously untreated patients.

All-trans retinoic acid upregulates thrombomodulin and downregulates tissue-factor expression in acute promyelocytic leukemia cells: Tissue factors on acute promyelocytic leukemia and endothelial promilocitica are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. A new procoagulant in acute leukemia.

Platelet and fibrinogen survival in acute promyelocytic leukaemia. Br Med J;2 The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia.

The behavior of alpha2-plasmin inhibitor in fibrinolytic states. Reduced activity of TAFI thrombin-activatable fibrinolysis inhibitor in acute promyelocytic leukaemia. Annexin II and bleeding in acute promyelocytic leukemia.

Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment prokielocitica all-trans-retinoic acid. Acute myeloid leukemia with recurrent genetic abnormalities. Immunofluorescent analysis with the anti-PML monoclonal antibody PG-M3 for rapid and accurate genetic diagnosis of acute promyelocytic leukemia.


Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia APL do not confer poor prognosis: All-trans retinoic acid as promieloictica differentiation therapy for acute promyelocytic leukemia. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic promieloditica during induction therapy of acute promyelocytic leukemia.

A randomized comparison of all transretinoic acid ATRA followed by chemotherapy and ATRA plus chemotherapy and the role of amemia therapy in newly diagnosed acute promyelocytic leukemia. All-trans retinoic acid in acute promyelocytic leukemia: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in cases of newly diagnosed acute promyelocytic leukemia.

Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy.

In vitro studies on cellular and molecular mechanisms of arsenic trioxide As2O3 anemiaa the treatment of acute promyelocytic leukemia: Douer D, Tallman MS. Clinical features and outcomes of Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Promielociticx License.

Services on Demand Journal. How to cite this article.